SECTORAL ASSET MANAGEMENT INC
Sector Allocation
- Healthcare99.3%$142.4M
- Technology0.7%$950,520
AUM History
13fpro.ai/research/fund/sectoral-asset-management-inc-1274413
Conviction and streaks
Diversifying · top 10 = 39.6%From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.
Largest positions — Q2 2026
CTNM
$11.9MSI
$8.7MLLY
$7.6MUNH
$5.5MJNJ
$4.6MORKA
$4.0MBNTX
$3.9MDFTX
$3.7MDXCM
$3.4MRCUS
$3.4MAMGN
$3.3MSMMT
$3.2MIRTC
$3.1MABBV
$3.1MMRK
$2.8MAVBP
$2.7MVRTX
$2.7MARGX
$2.6MGILD
$2.6MINSM
$2.5M
Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.
13fpro.ai/research/fund/sectoral-asset-management-inc-1274413
SECTORAL ASSET MANAGEMENT INC 13F holdings — Q2 2026
$143.3M portfolio (+18.7% QoQ) · 82 holdings · Q2 2026 13F · top 10 are 40% of the stock portfolio
$11.9M
8.3% of stocks
No changeThis quarter-42.6%Since filed9 qtrsHeld$8.7M
6.1% of stocks
No changeThis quarter-6.5%Since filed4 qtrsHeld$7.6M
5.3% of stocks
No changeThis quarter+8.4%Since filed10+ qtrsHeld$5.5M
3.8% of stocks
-12%This quarter+2.2%Since filed10+ qtrsHeld$4.6M
3.2% of stocks
No changeThis quarter+2.3%Since filed10+ qtrsHeld$4.0M
2.8% of stocks
NewThis quarter-18.6%Since filedNew this quarterHeld$3.9M
2.7% of stocks
+89%This quarter-6.7%Since filed10+ qtrsHeldAIQualityAI quality score is Pro: unlock with a free trialEst. buyEstimated buy price is Pro: unlock with a free trialAdded 2 qtrs in a row$3.7M
2.6% of stocks
NewThis quarter-16.3%Since filedNew this quarterHeld$3.4M
2.4% of stocks
+118%This quarter-12.5%Since filed6 qtrsHeld$3.4M
2.4% of stocks
+146%This quarter-39.8%Since filed10+ qtrsHeld
All holdings — SECTORAL ASSET MANAGEMENT INC (Q2 2026)
82 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.
| # | Company | Held | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | AMGEN INC | Healthcare | $3.3M | 2.3% | 9,210 | — | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 12 | Summit Therapeutics Inc. | Healthcare | $3.2M | 2.2% | 220K | +216% | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 13 | iRhythm Holdings, Inc. | Healthcare | $3.1M | 2.2% | 26K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 14 | AbbVie Inc. | Healthcare | $3.1M | 2.1% | 12K | — | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 15 | Merck & Co., Inc. | Healthcare | $2.8M | 1.9% | 21K | — | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 16 | ArriVent BioPharma, Inc. | Healthcare | $2.7M | 1.9% | 79K | +163% | 6 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 17 | VERTEX PHARMACEUTICALS INC / MA | Healthcare | $2.7M | 1.9% | 5,432 | -22% | 10+ qtrsTrimmed 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 18 | ARGENX SEadr | Healthcare | $2.6M | 1.8% | 2,831 | -21% | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 19 | GILEAD SCIENCES, INC. | Healthcare | $2.6M | 1.8% | 21K | -25% | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 20 | INSMED Inc | Healthcare | $2.5M | 1.7% | 23K | +18% | 10+ qtrsAdded 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 21 | Tectonic Therapeutic, Inc. | Healthcare | $2.4M | 1.7% | 71K | +273% | 5 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 22 | INTUITIVE SURGICAL INC | Healthcare | $2.3M | 1.6% | 5,850 | +11% | 10+ qtrsAdded 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 23 | Immatics N.V. | Healthcare | $2.3M | 1.6% | 225K | +237% | 5 qtrsAdded 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 24 | STRYKER CORP | Healthcare | $2.2M | 1.6% | 7,129 | +21% | 10+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 25 | Avalo Therapeutics, Inc. | Healthcare | $2.2M | 1.6% | 120K | New | 1 qtr | AI quality score is Pro: unlock with a free trial | 13F | |
| 26 | $CBIO | CRESCENT BIOPHARMA, INC. | Healthcare | $2.2M | 1.5% | 121K | New | |||
| 27 | $ROIV | Roivant Sciences Ltd. | Healthcare | $2.2M | 1.5% | 61K | +88% | |||
| 28 | $IQV | IQVIA HOLDINGS INC. | Healthcare | $2.1M | 1.5% | 11K | +31% | |||
| 29 | $PLSE | PULSE BIOSCIENCES, INC. | Healthcare | $1.9M | 1.3% | 68K | New | |||
| 30 | $DHR | DANAHER CORP /DE/ | Healthcare | $1.8M | 1.3% | 9,597 | — | |||
| 31 | $TMO | THERMO FISHER SCIENTIFIC INC. | Healthcare | $1.8M | 1.2% | 3,508 | — | |||
| 32 | $ABT | ABBOTT LABORATORIES | Healthcare | $1.6M | 1.1% | 18K | -29% | |||
| 33 | $ATEC | Alphatec Holdings, Inc. | Healthcare | $1.6M | 1.1% | 186K | New | |||
| 34 | $BSX | BOSTON SCIENTIFIC CORP | Healthcare | $1.6M | 1.1% | 36K | +4% | |||
| 35 | $TMDX | TransMedics Group, Inc. | Healthcare | $1.5M | 1.0% | 22K | New | |||
| 36 | $CYTK | CYTOKINETICS INC | Healthcare | $1.4M | 1.0% | 16K | +124% | |||
| 37 | $REGN | REGENERON PHARMACEUTICALS, INC. | Healthcare | $1.4M | 0.9% | 2,169 | -26% | |||
| 38 | $CVS | CVS HEALTH Corp | Healthcare | $1.3M | 0.9% | 13K | New | |||
| 39 | $EW | Edwards Lifesciences Corp | Healthcare | $1.3M | 0.9% | 15K | -14% | |||
| 40 | $TRVI | Trevi Therapeutics, Inc. | Healthcare | $1.2M | 0.8% | 66K | -12% | |||
| 41 | $BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $1.2M | 0.8% | 21K | — | |||
| 42 | $VERA | Vera Therapeutics, Inc. | Healthcare | $1.1M | 0.8% | 26K | — | |||
| 43 | $COGT | Cogent Biosciences, Inc. | Healthcare | $1.0M | 0.7% | 27K | +21% | |||
| 44 | $MDT | Medtronic plc | Healthcare | $876K | 0.6% | 11K | — | |||
| 45 | $TARS | Tarsus Pharmaceuticals, Inc. | Healthcare | $836K | 0.6% | 13K | +18% | |||
| 46 | $KURA | Kura Oncology, Inc. | Healthcare | $784K | 0.6% | 71K | — | |||
| 47 | $CNC | CENTENE CORP | Healthcare | $770K | 0.5% | 12K | New | |||
| 48 | $UTHR | UNITED THERAPEUTICS Corp | Healthcare | $742K | 0.5% | 1,370 | -20% | |||
| 49 | $HNGE | Hinge Health, Inc. | Technology | $726K | 0.5% | 8,744 | -29% | |||
| 50 | $NKTR | NEKTAR THERAPEUTICS | Healthcare | $706K | 0.5% | 10K | -7% | |||
| 51 | $ALNY | ALNYLAM PHARMACEUTICALS, INC. | Healthcare | $695K | 0.5% | 2,310 | — | |||
| 52 | $ASND | Ascendis Pharma A/S | Healthcare | $685K | 0.5% | 2,570 | -8% | |||
| 53 | $PFE | PFIZER INC | Healthcare | $662K | 0.5% | 28K | — | |||
| 54 | $ARDX | ARDELYX, INC. | Healthcare | $624K | 0.4% | 122K | — | |||
| 55 | $PRVA | Privia Health Group, Inc. | Healthcare | $621K | 0.4% | 24K | -11% | |||
| 56 | $PTCT | PTC THERAPEUTICS, INC. | Healthcare | $609K | 0.4% | 7,470 | +12% | |||
| 57 | $IONS | IONIS PHARMACEUTICALS INC | Healthcare | $571K | 0.4% | 7,200 | — | |||
| 58 | $AGMB | AgomAb Therapeutics NV | Healthcare | $565K | 0.4% | 44K | — | |||
| 59 | $BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $541K | 0.4% | 9,450 | — | |||
| 60 | $ONC | BeOne Medicines Ltd. | Healthcare | $533K | 0.4% | 1,870 | — | |||
| 61 | $HUM | HUMANA INC | Healthcare | $497K | 0.3% | 1,250 | New | |||
| 62 | $JAZZ | Jazz Pharmaceuticals plc | Healthcare | $422K | 0.3% | 1,750 | — | |||
| 63 | $RPRX | Royalty Pharma plc | Healthcare | $404K | 0.3% | 7,200 | — | |||
| 64 | $BIIB | BIOGEN INC. | Healthcare | $400K | 0.3% | 1,850 | — | |||
| 65 | $MLYS | Mineralys Therapeutics, Inc. | Healthcare | $393K | 0.3% | 15K | -54% | |||
| 66 | $ILMN | ILLUMINA, INC. | Healthcare | $375K | 0.3% | 2,132 | — | |||
| 67 | $AXSM | Axsome Therapeutics, Inc. | Healthcare | $367K | 0.3% | 1,500 | — | |||
| 68 | $SNDX | Syndax Pharmaceuticals Inc | Healthcare | $343K | 0.2% | 16K | -51% | |||
| 69 | $RVMD | Revolution Medicines, Inc. | Healthcare | $343K | 0.2% | 1,830 | — | |||
| 70 | $ABVX | Abivax S.A. | Healthcare | $312K | 0.2% | 2,340 | — | |||
| 71 | $BBIO | BridgeBio Pharma, Inc. | Healthcare | $305K | 0.2% | 4,100 | -49% | |||
| 72 | $MRNA | Moderna, Inc. | Healthcare | $305K | 0.2% | 4,350 | — | |||
| 73 | $GH | Guardant Health, Inc. | Healthcare | $297K | 0.2% | 1,980 | — | |||
| 74 | $INCY | INCYTE CORP | Healthcare | $266K | 0.2% | 2,350 | — | |||
| 75 | $ORIC | Oric Pharmaceuticals, Inc. | Healthcare | $255K | 0.2% | 24K | — | |||
| 76 | $SPRY | ARS Pharmaceuticals, Inc. | Healthcare | $239K | 0.2% | 30K | -62% | |||
| 77 | $GPCR | Structure Therapeutics Inc. | Healthcare | $232K | 0.2% | 4,325 | -69% | |||
| 78 | $MEDP | Medpace Holdings, Inc. | Healthcare | $228K | 0.2% | 430 | — | |||
| 79 | $TEM | Tempus AI, Inc. | Technology | $225K | 0.2% | 3,880 | New | |||
| 80 | $CRBP | Corbus Pharmaceuticals Holdings, Inc. | Healthcare | $188K | 0.1% | 20K | New | |||
| 81 | $PALI | PALISADE BIO, INC. | Healthcare | $184K | 0.1% | 88K | — | |||
| 82 | $ENGN | enGene Therapeutics Inc. | Healthcare | $38K | 0.0% | 22K | New |
What changed in Q2 2026
Against the previous quarter's 13F: 14 new, 17 added to, 18 trimmed, 9 sold out. Share-count changes; largest moves by dollar size first.
New positions (14)
$ORKAOruka Therapeutics, Inc.$4.0M
first bought this quarter
$DFTXDefinium Therapeutics, Inc.$3.7M
first bought this quarter
$IRTCiRhythm Holdings, Inc.$3.1M
first bought this quarter
$AVTXAvalo Therapeutics, Inc.$2.2M
first bought this quarter
$CBIOCRESCENT BIOPHARMA, INC.$2.2M
first bought this quarter
$PLSEPULSE BIOSCIENCES, INC.$1.9M
first bought this quarter
+8 more in the Excel export
Added to (17)
$SMMTSummit Therapeutics Inc.+216%
now $3.2M · held 10+ qtrs
$RCUSArcus Biosciences, Inc.+146%
now $3.4M · held 10+ qtrs
$DXCMDEXCOM INC+118%
now $3.4M · held 6 qtrs
$BNTXBioNTech SE+89%
now $3.9M · held 10+ qtrs, 2 adds in a row
$TECXTectonic Therapeutic, Inc.+273%
now $2.4M · held 5 qtrs
$AVBPArriVent BioPharma, Inc.+163%
now $2.7M · held 6 qtrs
+11 more in the Excel export
Trimmed (18)
$GILDGILEAD SCIENCES, INC.-25%
now $2.6M · held 10+ qtrs
$VRTXVERTEX PHARMACEUTICALS INC / MA-22%
now $2.7M · held 10+ qtrs, 2 trims in a row
$UNHUNITEDHEALTH GROUP INC-12%
now $5.5M · held 10+ qtrs
$ABTABBOTT LABORATORIES-29%
now $1.6M · held 10+ qtrs
$ARGXARGENX SE-21%
now $2.6M · held 10+ qtrs
$GPCRStructure Therapeutics Inc.-69%
now $232K · held 10+ qtrs, 3 trims in a row
+12 more in the Excel export
Holdings by quarter
Every 13F SECTORAL ASSET MANAGEMENT INC has filed, 41 earlier quarters. Pick one to see what it held then.
Is it too late to follow SECTORAL ASSET MANAGEMENT?
Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.
Average quality of SECTORAL ASSET MANAGEMENT's top 20 holdings: 60/100 (our AI quality score, weighted by position size; 13 of the 20 are scored)
Top 10 since filing
-14.4%
Value-weighted move of the 10 largest stock positions
Turnover
19%
Last quarter; 65% over the last 4
Top 10 weight
40%
Share of the stock portfolio in its 10 largest positions
Held 4+ quarters
78%
Share of portfolio value in positions held a year or more
Highest-quality names it owns(among its 100 largest positions)
The 8 highest-scoring companies in this portfolio are a Pro feature.
How these are measured
- Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
- Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
- Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
- Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
- Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.
Portfolio Overview
SECTORAL ASSET MANAGEMENT INC disclosed 82 positions worth $143.3M in its Form 13F-HR for Q2 2026, led by $CTNM (Contineum Therapeutics, Inc.) at 8.3% of the equity portfolio, followed by $SI and $LLY. During the quarter the fund opened 14 new positions and exited 9 — including a new stake in $ORKA and a full exit from $EVMN. The portfolio is most concentrated in Healthcare (99.3% of disclosed assets). All figures are sourced directly from SECTORAL ASSET MANAGEMENT INC’s Form 13F-HR filing with the SEC under CIK 1274413.
Funds like this
managers whose biggest positions overlap SECTORAL ASSET MANAGEMENT'sBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
AI-Powered Hedge Fund Analysis: SECTORAL ASSET MANAGEMENT INC
13F Pro is an AI hedge fund tracker and stock research platform. For SECTORAL ASSET MANAGEMENT INC (SEC CIK: 1274413), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in SECTORAL ASSET MANAGEMENT INC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.